Overview

Pathophysiology and Prevention of Perioperative Myocardial Injury: A Prospective Randomized Controlled Trial

Status:
Unknown status

Trial end date:
2017-12-01

Target enrollment:
0

Participant gender:
All

Summary

Working hypothesis and aims: 1) To explore the pathophysiology of postoperative troponin elevations and 2) whether ranolazine, a new anti-ischemic drug that has no effect on blood pressure or heart rate, prevents postoperative myocardial injury.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Hadassah Medical Organization

Treatments:

Ranolazine

Criteria

Inclusion Criteria:

- All patients age 18 and above, undergoing major surgery that require at least 24 hours
(overnight) stay in the post anesthesia care unit (PACU) or intensive care unit (ICU), and
who either have known history of CAD or at least 3 of the following Revised Cardiac Risk
Index (RCRI) criteria29F17: 1) high-risk type of surgery, 2) history of ischemic heart
disease, 3) history of congestive heart failure, 4) history of cerebrovascular disease, 5)
diabetes mellitus, 6) renal failure (creatinine > 2mg/ml).

Exclusion Criteria:

- Pregnancy, LV ejection fraction ≤35%, patients with severe valvular disease, patients
with poor echocardiographic images, patients who cannot swallow the pill after
surgery, refusal to participate